|

A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin

RECRUITINGPhase 2Sponsored by Eli Lilly and Company
Actively Recruiting
PhasePhase 2
SponsorEli Lilly and Company
Started2025-10-13
Est. completion2026-11
Eligibility
Age18 Years – 70 Years
Healthy vol.Accepted
Locations20 sites
View on ClinicalTrials.gov →

NCT07215312

Summary

The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.

Eligibility

Age: 18 Years – 70 YearsHealthy volunteers accepted
Inclusion Criteria:

* Have type 2 diabetes
* Are receiving ≥20 units of basal insulin per day and ≤55 units/day and ≤1.5 units/kg/day at screening
* Have hemoglobin A1c (HbA1c) 7.5% to 10.5% inclusive
* Have a body mass index (BMI) of 20 or higher and less than 35 kilograms per square meter (kg/m2)

Exclusion Criteria:

* Have type 1 diabetes

Conditions2

DiabetesDiabetes Mellitus, Type 2

Locations20 sites

Tucson Clinical Research Institute
Tucson, Arizona, 85712
Girish Karamchandani
Encompass Clinical Research
Spring Valley, California, 91978
619-660-9068
University Clinical Investigators, Inc.
Tustin, California, 92780
714-734-7944
Tampa Bay Medical Research
Clearwater, Florida, 33761
727-724-3316
Encore Medical Research
Hollywood, Florida, 33024
954-400-1725

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.